{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T09:26:52Z","timestamp":1773480412542,"version":"3.50.1"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,3,18]],"date-time":"2021-03-18T00:00:00Z","timestamp":1616025600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,3,18]],"date-time":"2021-03-18T00:00:00Z","timestamp":1616025600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005416","name":"Norges Forskningsr\u00e5d","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005416","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008730","name":"Kreftforeningen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008730","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000781","name":"European Research Council","doi-asserted-by":"publisher","award":["ERC-2015-Adg_695376"],"award-info":[{"award-number":["ERC-2015-Adg_695376"]}],"id":[{"id":"10.13039\/501100000781","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006313","name":"Barncancerfonden","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006313","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012538","name":"Swedish Cancer Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012538","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006095","name":"Helse S\u00f8r-\u00d8st RHF","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006095","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Chemo-immunotherapy has improved survival in B-cell lymphoma patients, but refractory\/relapsed diseases still represent a major challenge, urging for development of new therapeutics. Karonudib (TH1579) was developed to inhibit MTH1, an enzyme preventing oxidized dNTP-incorporation in DNA. MTH1 is highly upregulated in tumor biopsies from patients with diffuse large B-cell lymphoma (DLBCL) and Burkitt lymphoma, hence confirming a rationale for targeting MTH1. Here, we tested the efficacy of karonudib in vitro and in preclinical B-cell lymphoma models. Using a range of B-cell lymphoma cell lines, karonudib strongly reduced viability at concentrations well tolerated by activated normal B cells. In B-cell lymphoma cells, karonudib increased incorporation of 8-oxo-dGTP into DNA, and prominently induced prometaphase arrest and apoptosis due to failure in spindle assembly. MTH1 knockout cell lines were less sensitive to karonudib-induced apoptosis, but were displaying cell cycle arrest phenotype similar to the wild type cells, indicating a dual inhibitory role of the drug. Karonudib was highly potent as single agent in two different lymphoma xenograft models, including an ABC DLBCL patient derived xenograft, leading to prolonged survival and fully controlled tumor growth. Together, our preclinical findings provide a rationale for further clinical testing of karonudib in B-cell lymphoma.<\/jats:p>","DOI":"10.1038\/s41598-021-85613-8","type":"journal-article","created":{"date-parts":[[2021,3,18]],"date-time":"2021-03-18T16:47:41Z","timestamp":1616086061000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Karonudib has potent anti-tumor effects in preclinical models of B-cell lymphoma"],"prefix":"10.1038","volume":"11","author":[{"given":"Morten P.","family":"Oksvold","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ulrika Warpman","family":"Berglund","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helge","family":"Gad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Baoyan","family":"Bai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Trond","family":"Stokke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Idun Dale","family":"Rein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Therese","family":"Pham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kumar","family":"Sanjiv","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Geir Frode","family":"\u00d8y","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jens Henrik","family":"Norum","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erlend B.","family":"Smeland","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"June H.","family":"Myklebust","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Helleday","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thea Kristin","family":"V\u00e5tsveen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,3,18]]},"reference":[{"key":"85613_CR1","doi-asserted-by":"publisher","first-page":"2016","DOI":"10.1182\/asheducation-2016.1.366","volume":"366\u2013378","author":"B Coiffier","year":"2016","unstructured":"Coiffier, B. & Sarkozy, C. Diffuse large B-cell lymphoma: R-CHOP failure-what to do?. Hematol. Am. Soc. Hematol. Educ. Program 366\u2013378, 2016. https:\/\/doi.org\/10.1182\/asheducation-2016.1.366 (2016).","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program"},{"key":"85613_CR2","doi-asserted-by":"publisher","first-page":"4184","DOI":"10.1200\/JCO.2010.28.1618","volume":"28","author":"C Gisselbrecht","year":"2010","unstructured":"Gisselbrecht, C. et al. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J. Clin. Oncol. 28, 4184\u20134190. https:\/\/doi.org\/10.1200\/JCO.2010.28.1618 (2010).","journal-title":"J. Clin. Oncol."},{"key":"85613_CR3","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/j.beha.2018.07.013","volume":"31","author":"C Casulo","year":"2018","unstructured":"Casulo, C. & Friedberg, J. W. Burkitt lymphoma\u2014A rare but challenging lymphoma. Best Pract. Res. Clin. Haematol. 31, 279\u2013284. https:\/\/doi.org\/10.1016\/j.beha.2018.07.013 (2018).","journal-title":"Best Pract. Res. Clin. Haematol."},{"key":"85613_CR4","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.1182\/blood-2018-03-791392","volume":"132","author":"K Maddocks","year":"2018","unstructured":"Maddocks, K. Update on mantle cell lymphoma. Blood 132, 1647\u20131656. https:\/\/doi.org\/10.1182\/blood-2018-03-791392 (2018).","journal-title":"Blood"},{"key":"85613_CR5","doi-asserted-by":"publisher","first-page":"2275","DOI":"10.1093\/annonc\/mdw429","volume":"27","author":"UW Berglund","year":"2016","unstructured":"Berglund, U. W. et al. Validation and development of MTH1 inhibitors for treatment of cancer. Ann. Oncol. 27, 2275\u20132283. https:\/\/doi.org\/10.1093\/annonc\/mdw429 (2016).","journal-title":"Ann. Oncol."},{"key":"85613_CR6","doi-asserted-by":"publisher","first-page":"23524","DOI":"10.1016\/S0021-9258(19)49494-5","volume":"268","author":"K Sakumi","year":"1993","unstructured":"Sakumi, K. et al. Cloning and expression of cDNA for a human enzyme that hydrolyzes 8-oxo-dGTP, a mutagenic substrate for DNA synthesis. J. Biol. Chem. 268, 23524\u201323530 (1993).","journal-title":"J. Biol. Chem."},{"key":"85613_CR7","doi-asserted-by":"publisher","first-page":"18201","DOI":"10.1074\/jbc.274.26.18201","volume":"274","author":"K Fujikawa","year":"1999","unstructured":"Fujikawa, K. et al. The oxidized forms of dATP are substrates for the human MutT homologue, the hMTH1 protein. J. Biol. Chem. 274, 18201\u201318205 (1999).","journal-title":"J. Biol. Chem."},{"key":"85613_CR8","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gky896","author":"AS Jemth","year":"2018","unstructured":"Jemth, A. S. et al. MutT homologue 1 (MTH1) catalyzes the hydrolysis of mutagenic O6-methyl-dGTP. Nucleic Acids Res. https:\/\/doi.org\/10.1093\/nar\/gky896 (2018).","journal-title":"Nucleic Acids Res."},{"key":"85613_CR9","doi-asserted-by":"publisher","first-page":"37965","DOI":"10.1074\/jbc.M306201200","volume":"278","author":"D Yoshimura","year":"2003","unstructured":"Yoshimura, D. et al. An oxidized purine nucleoside triphosphatase, MTH1, suppresses cell death caused by oxidative stress. J. Biol. Chem. 278, 37965\u201337973. https:\/\/doi.org\/10.1074\/jbc.M306201200 (2003).","journal-title":"J. Biol. Chem."},{"key":"85613_CR10","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/S0027-5107(01)00108-7","volume":"477","author":"T Tsuzuki","year":"2001","unstructured":"Tsuzuki, T., Egashira, A. & Kura, S. Analysis of MTH1 gene function in mice with targeted mutagenesis. Mutat. Res. 477, 71\u201378 (2001).","journal-title":"Mutat. Res."},{"key":"85613_CR11","doi-asserted-by":"publisher","first-page":"17843","DOI":"10.1074\/jbc.272.28.17843","volume":"272","author":"H Oda","year":"1997","unstructured":"Oda, H., Nakabeppu, Y., Furuichi, M. & Sekiguchi, M. Regulation of expression of the human MTH1 gene encoding 8-oxo-dGTPase. Alternative splicing of transcription products. J. Biol. Chem. 272, 17843\u201317850 (1997).","journal-title":"J. Biol. Chem."},{"key":"85613_CR12","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1093\/nar\/29.2.449","volume":"29","author":"K Fujikawa","year":"2001","unstructured":"Fujikawa, K., Kamiya, H., Yakushiji, H., Nakabeppu, Y. & Kasai, H. Human MTH1 protein hydrolyzes the oxidized ribonucleotide, 2-hydroxy-ATP. Nucleic Acids Res. 29, 449\u2013454 (2001).","journal-title":"Nucleic Acids Res."},{"key":"85613_CR13","doi-asserted-by":"publisher","DOI":"10.1101\/575290","author":"H Gad","year":"2019","unstructured":"Gad, H. et al. MTH1 promotes mitotic progression to avoid oxidative DNA damage in cancer cells. bioRxiv. https:\/\/doi.org\/10.1101\/575290 (2019).","journal-title":"bioRxiv."},{"key":"85613_CR14","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-19-0883","author":"SG Rudd","year":"2020","unstructured":"Rudd, S. G. et al. MTH1 inhibitor TH588 disturbs mitotic progression and induces mitosis-dependent accumulation of genomic 8-oxodG. Cancer Res. https:\/\/doi.org\/10.1158\/0008-5472.CAN-19-0883 (2020).","journal-title":"Cancer Res."},{"key":"85613_CR15","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1038\/nature13181","volume":"508","author":"H Gad","year":"2014","unstructured":"Gad, H. et al. MTH1 inhibition eradicates cancer by preventing sanitation of the dNTP pool. Nature 508, 215\u2013221. https:\/\/doi.org\/10.1038\/nature13181 (2014).","journal-title":"Nature"},{"key":"85613_CR16","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1038\/s41419-018-0865-6","volume":"9","author":"BO Einarsdottir","year":"2018","unstructured":"Einarsdottir, B. O. et al. A patient-derived xenograft pre-clinical trial reveals treatment responses and a resistance mechanism to karonudib in metastatic melanoma. Cell Death Dis. 9, 810. https:\/\/doi.org\/10.1038\/s41419-018-0865-6 (2018).","journal-title":"Cell Death Dis."},{"key":"85613_CR17","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1111\/bph.14542","volume":"176","author":"A Lallo","year":"2019","unstructured":"Lallo, A. et al. Ex vivo culture of cells derived from circulating tumour cell xenograft to support small cell lung cancer research and experimental therapeutics. Br. J. Pharmacol. 176, 436\u2013450. https:\/\/doi.org\/10.1111\/bph.14542 (2019).","journal-title":"Br. J. Pharmacol."},{"key":"85613_CR18","doi-asserted-by":"publisher","first-page":"175883591986696","DOI":"10.1177\/1758835919866960","volume":"11","author":"X Hua","year":"2019","unstructured":"Hua, X. et al. Karonudib is a promising anticancer therapy in hepatocellular carcinoma. Ther. Adv. Med. Oncol. 11, 1758835919866960. https:\/\/doi.org\/10.1177\/1758835919866960 (2019).","journal-title":"Ther. Adv. Med. Oncol."},{"key":"85613_CR19","unstructured":"Scobie, M. H., Koolmeister, T., Deques, T., Decrose, S., Jacques-Cordonnier, M., Marie-Caroline, J. Pyrimidine-2,4-diamine derivatives for treatment of cancer. Sweden patent WO2014084778 (2014)."},{"key":"85613_CR20","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s13045-018-0561-0","volume":"11","author":"TK Vatsveen","year":"2018","unstructured":"Vatsveen, T. K. et al. Artesunate shows potent anti-tumor activity in B-cell lymphoma. J. Hematol. Oncol. 11, 23. https:\/\/doi.org\/10.1186\/s13045-018-0561-0 (2018).","journal-title":"J. Hematol. Oncol."},{"key":"85613_CR21","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/0022-1759(92)90228-L","volume":"146","author":"AM Rasmussen","year":"1992","unstructured":"Rasmussen, A. M., Smeland, E. B., Erikstein, B. K., Caignault, L. & Funderud, S. A new method for detachment of Dynabeads from positively selected B lymphocytes. J. Immunol. Methods 146, 195\u2013202 (1992).","journal-title":"J. Immunol. Methods"},{"key":"85613_CR22","doi-asserted-by":"publisher","first-page":"3261","DOI":"10.1080\/15384101.2015.1087617","volume":"14","author":"ID Rein","year":"2015","unstructured":"Rein, I. D. et al. New distinct compartments in the G2 phase of the cell cycle defined by the levels of gammaH2AX. Cell Cycle 14, 3261\u20133269. https:\/\/doi.org\/10.1080\/15384101.2015.1087617 (2015).","journal-title":"Cell Cycle"},{"key":"85613_CR23","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1667\/RR3235","volume":"162","author":"KS Landsverk","year":"2004","unstructured":"Landsverk, K. S., Lyng, H. & Stokke, T. The response of malignant B lymphocytes to ionizing radiation: Cell cycle arrest, apoptosis and protection against the cytotoxic effects of the mitotic inhibitor nocodazole. Radiat. Res. 162, 405\u2013415 (2004).","journal-title":"Radiat. Res."},{"key":"85613_CR24","doi-asserted-by":"publisher","unstructured":"Kotecha, N., Krutzik, P. O. & Irish, J. M. Web-based analysis and publication of flow cytometry experiments. in Current protocols in cytometry\/editorial board, J. Paul Robinson, managing editor ... [et al.] Chapter 10, Unit 10 17. https:\/\/doi.org\/10.1002\/0471142956.cy1017s53 (2010).","DOI":"10.1002\/0471142956.cy1017s53"},{"key":"85613_CR25","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1038\/ng1180","volume":"34","author":"VK Mootha","year":"2003","unstructured":"Mootha, V. K. et al. PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat. Genet. 34, 267\u2013273. https:\/\/doi.org\/10.1038\/ng1180 (2003).","journal-title":"Nat. Genet."},{"key":"85613_CR26","doi-asserted-by":"publisher","first-page":"15545","DOI":"10.1073\/pnas.0506580102","volume":"102","author":"A Subramanian","year":"2005","unstructured":"Subramanian, A. et al. Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. USA 102, 15545\u201315550. https:\/\/doi.org\/10.1073\/pnas.0506580102 (2005).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"85613_CR27","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.cels.2015.12.004","volume":"1","author":"A Liberzon","year":"2015","unstructured":"Liberzon, A. et al. The Molecular Signatures Database (MSigDB) hallmark gene set collection. Cell Syst. 1, 417\u2013425. https:\/\/doi.org\/10.1016\/j.cels.2015.12.004 (2015).","journal-title":"Cell Syst."},{"key":"85613_CR28","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1182\/blood-2013-07-512392","volume":"123","author":"M Brodtkorb","year":"2014","unstructured":"Brodtkorb, M. et al. Whole-genome integrative analysis reveals expression signatures predicting transformation in follicular lymphoma. Blood 123, 1051\u20131054. https:\/\/doi.org\/10.1182\/blood-2013-07-512392 (2014).","journal-title":"Blood"},{"key":"85613_CR29","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1038\/35000501","volume":"403","author":"AA Alizadeh","year":"2000","unstructured":"Alizadeh, A. A. et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403, 503\u2013511. https:\/\/doi.org\/10.1038\/35000501 (2000).","journal-title":"Nature"},{"key":"85613_CR30","doi-asserted-by":"publisher","first-page":"2431","DOI":"10.1056\/NEJMoa055759","volume":"354","author":"SS Dave","year":"2006","unstructured":"Dave, S. S. et al. Molecular diagnosis of Burkitt\u2019s lymphoma. N. Engl. J. Med. 354, 2431\u20132442. https:\/\/doi.org\/10.1056\/NEJMoa055759 (2006).","journal-title":"N. Engl. J. Med."},{"key":"85613_CR31","doi-asserted-by":"publisher","first-page":"e79602","DOI":"10.1371\/journal.pone.0079602","volume":"8","author":"N Bethge","year":"2013","unstructured":"Bethge, N. et al. Identification of highly methylated genes across various types of B-cell non-hodgkin lymphoma. PLoS ONE 8, e79602. https:\/\/doi.org\/10.1371\/journal.pone.0079602 (2013).","journal-title":"PLoS ONE"},{"key":"85613_CR32","doi-asserted-by":"publisher","first-page":"2251","DOI":"10.1084\/jem.20080809","volume":"205","author":"V Brune","year":"2008","unstructured":"Brune, V. et al. Origin and pathogenesis of nodular lymphocyte-predominant Hodgkin lymphoma as revealed by global gene expression analysis. J. Exp. Med. 205, 2251\u20132268. https:\/\/doi.org\/10.1084\/jem.20080809 (2008).","journal-title":"J. Exp. Med."},{"key":"85613_CR33","doi-asserted-by":"publisher","first-page":"3367","DOI":"10.1016\/j.febslet.2012.07.027","volume":"586","author":"M Bakkebo","year":"2012","unstructured":"Bakkebo, M. et al. SARA is dispensable for functional TGF-beta signaling. FEBS Lett. 586, 3367\u20133372. https:\/\/doi.org\/10.1016\/j.febslet.2012.07.027 (2012).","journal-title":"FEBS Lett."},{"key":"85613_CR34","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.cels.2019.05.009","volume":"9","author":"JC Patterson","year":"2019","unstructured":"Patterson, J. C. et al. VISAGE reveals a targetable mitotic spindle vulnerability in cancer cells. Cell Syst. 9, 74\u201392.e78. https:\/\/doi.org\/10.1016\/j.cels.2019.05.009 (2019).","journal-title":"Cell Syst."},{"key":"85613_CR35","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1007\/978-1-0716-0290-4_25","volume":"2115","author":"B Bai","year":"2020","unstructured":"Bai, B., Myklebust, J. H. & Walchli, S. Gene editing in B-lymphoma cell lines using CRISPR\/Cas9 technology. Methods Mol. Biol. 2115, 445\u2013454. https:\/\/doi.org\/10.1007\/978-1-0716-0290-4_25 (2020).","journal-title":"Methods Mol. Biol."},{"key":"85613_CR36","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1007\/s10278-004-1014-6","volume":"17","author":"A Rosset","year":"2004","unstructured":"Rosset, A., Spadola, L. & Ratib, O. OsiriX: An open-source software for navigating in multidimensional DICOM images. J. Digit. Imaging 17, 205\u2013216. https:\/\/doi.org\/10.1007\/s10278-004-1014-6 (2004).","journal-title":"J. Digit. Imaging"},{"key":"85613_CR37","doi-asserted-by":"publisher","first-page":"3135","DOI":"10.1002\/eji.201141558","volume":"41","author":"K Huse","year":"2011","unstructured":"Huse, K. et al. Bone morphogenetic proteins inhibit CD40L\/IL-21-induced Ig production in human B cells: Differential effects of BMP-6 and BMP-7. Eur. J. Immunol. 41, 3135\u20133145. https:\/\/doi.org\/10.1002\/eji.201141558 (2011).","journal-title":"Eur. J. Immunol."},{"key":"85613_CR38","doi-asserted-by":"publisher","first-page":"14667","DOI":"10.1038\/s41598-019-51205-w","volume":"9","author":"N Gul","year":"2019","unstructured":"Gul, N. et al. The MTH1 inhibitor TH588 is a microtubule-modulating agent that eliminates cancer cells by activating the mitotic surveillance pathway. Sci. Rep. 9, 14667. https:\/\/doi.org\/10.1038\/s41598-019-51205-w (2019).","journal-title":"Sci. Rep."},{"key":"85613_CR39","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1093\/annonc\/mdu158","volume":"25","author":"T Helleday","year":"2014","unstructured":"Helleday, T. Cancer phenotypic lethality, exemplified by the non-essential MTH1 enzyme being required for cancer survival. Ann. Oncol. 25, 1253\u20131255. https:\/\/doi.org\/10.1093\/annonc\/mdu158 (2014).","journal-title":"Ann. Oncol."},{"key":"85613_CR40","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1038\/362849a0","volume":"362","author":"AR Clarke","year":"1993","unstructured":"Clarke, A. R. et al. Thymocyte apoptosis induced by p53-dependent and independent pathways. Nature 362, 849\u2013852. https:\/\/doi.org\/10.1038\/362849a0 (1993).","journal-title":"Nature"},{"key":"85613_CR41","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1016\/0092-8674(93)90719-7","volume":"74","author":"SW Lowe","year":"1993","unstructured":"Lowe, S. W., Ruley, H. E., Jacks, T. & Housman, D. E. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 74, 957\u2013967 (1993).","journal-title":"Cell"},{"key":"85613_CR42","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1002\/1097-0215(20000720)89:4<313::AID-IJC1>3.0.CO;2-D","volume":"89","author":"T Stokke","year":"2000","unstructured":"Stokke, T. et al. Oncogenic aberrations in the p53 pathway are associated with a high S phase fraction and poor patient survival in B-cell Non-Hodgkin\u2019s lymphoma. Int. J. Cancer 89, 313\u2013324 (2000).","journal-title":"Int. J. Cancer"},{"key":"85613_CR43","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1111\/ejh.12171","volume":"91","author":"I Fiskvik","year":"2013","unstructured":"Fiskvik, I. et al. Karyotyping of diffuse large B-cell lymphomas: Loss of 17p is associated with poor patient outcome. Eur. J. Haematol. 91, 332\u2013338. https:\/\/doi.org\/10.1111\/ejh.12171 (2013).","journal-title":"Eur. J. Haematol."},{"key":"85613_CR44","doi-asserted-by":"publisher","first-page":"1742","DOI":"10.3109\/10428194.2014.970550","volume":"56","author":"I Fiskvik","year":"2015","unstructured":"Fiskvik, I. et al. Combining MYC, BCL2 and TP53 gene and protein expression alterations improves risk stratification in diffuse large B-cell lymphoma. Leuk. Lymphoma 56, 1742\u20131749. https:\/\/doi.org\/10.3109\/10428194.2014.970550 (2015).","journal-title":"Leuk. Lymphoma"},{"key":"85613_CR45","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1056\/NEJM199708213370804","volume":"337","author":"A Ichikawa","year":"1997","unstructured":"Ichikawa, A. et al. Mutations of the p53 gene as a prognostic factor in aggressive B-cell lymphoma. N. Engl. J. Med. 337, 529\u2013534. https:\/\/doi.org\/10.1056\/NEJM199708213370804 (1997).","journal-title":"N. Engl. J. Med."},{"key":"85613_CR46","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1182\/blood-2016-02-636316","volume":"129","author":"P Sesques","year":"2017","unstructured":"Sesques, P. & Johnson, N. A. Approach to the diagnosis and treatment of high-grade B-cell lymphomas with MYC and BCL2 and\/or BCL6 rearrangements. Blood 129, 280\u2013288. https:\/\/doi.org\/10.1182\/blood-2016-02-636316 (2017).","journal-title":"Blood"},{"key":"85613_CR47","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.31646","author":"PA Riedell","year":"2018","unstructured":"Riedell, P. A. & Smith, S. M. Double hit and double expressors in lymphoma: Definition and treatment. Cancer https:\/\/doi.org\/10.1002\/cncr.31646 (2018).","journal-title":"Cancer"},{"key":"85613_CR48","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaw8412","author":"A Lin","year":"2019","unstructured":"Lin, A. et al. Off-target toxicity is a common mechanism of action of cancer drugs undergoing clinical trials. Sci. Transl. Med. https:\/\/doi.org\/10.1126\/scitranslmed.aaw8412 (2019).","journal-title":"Sci. Transl. Med."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-85613-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-85613-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-85613-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T05:31:45Z","timestamp":1670045505000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-85613-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,18]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["85613"],"URL":"https:\/\/doi.org\/10.1038\/s41598-021-85613-8","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,18]]},"assertion":[{"value":"22 September 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 February 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A patent has been filed with TH588 and TH1579 where T.H. is listed as inventor. The Intellectual Property Right is owned by the non-profit Thomas Helleday Foundation for Medical Research (THF). T.H., U.W.B., K.S. and H.G. are board members of the THF. THF is sponsor for on-going clinical trial with TH1579. Oxcia AB is assisting THF in TH1579 clinical trial and U.W.B is chairman of Oxcia AB. H.G., U.W.B., T.P., K.S. and T.H. are shareholders in Oxcia AB. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"6317"}}